Swiss doctors limit remdesivir use as government looks to procure more US firm Gilead set the price for remdesivir at CHF380.50 per dose for developed countries. Multiple doses are a typical treatment course. Mtva - Media Service Support And Asset Management Fund Swiss doctors are taking a cautious approach to the use of remdesivir for treating Covid-19 in the midst of emerging evidence from the World Health Organisation on the drug's ineffectiveness. Yet, the Swiss authorities moved ahead with an authorisation of the treatment and are making efforts to procure more of it. This content was published on December 10, 2020 - 11:00